Results 111 to 120 of about 1,327 (186)

Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review [PDF]

Background: Migraine is the second most common prevalent disorder worldwide and is a top cause of disability with a substantial economic burden. Many preventive migraine medications have notable side effects that affect different body organs.
Aksentyte, Aiva, Brown, Anna, Davies, Natasha, Duncan, Callum, Matharu, Manjit, Mistry, Hema, Naghdi, Seyran, Underwood, Martin   +7 more
core  

Revisión bibliográfica de los gepantes para el tratamiento de la migraña [PDF]

La migraña es una enfermedad neurológica que cursa con dolor de cabeza pulsátil, de intensidad moderada o intensa, que puede asociarse con náuseas, vómitos, fotofobia y fonofobia. Recientemente, los gepantes han emergido como una nueva opción terapéutica
del Paso García, Ana Isabel
core  

Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial. [PDF]

PLoS One
Franjic D, Fountaine RJ, Nalpas C, Goswami B, Fullerton T.   +4 more
europepmc   +1 more source

Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine

Drug Design, Development and Therapy
Mengyi Li, Siyong Huang, Jiabao Li, Xiao Hu, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Li M, Huang S, Li J, Hu X, Chen J
doaj  

Migraine-induced cochlear injury triggers ZBP1-mediated PANoptosis via CGRP signaling. [PDF]

J Headache Pain
Xu W, Zhai N, Chen J, Zhou S, Tian E, Guo Z, Zhou Z, Yu X, Zhai Z, Zhang X, Wang Y, Ma X, Lu Y, Zhang S.   +13 more
europepmc   +1 more source

Investigation of the rimegepant effect on cerebral and extracerebral arteries during migraine attacks: a longitudinal magnetic resonance angiography study. [PDF]

Brain Commun
Chaudhry BA, Younis S, Al-Mashat H, Gozalov E, Amin TM, de Koning PJH, Larsson HBW, Amin FM.   +7 more
europepmc   +1 more source

Rimegepant for migraine.

Australian prescriber
  +5 more sources

A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine. [PDF]

Headache
Lim CN, Mo G, Bhardwaj R, Comisar CM, Emerson BL, Matschke KT, Fisniku O, Bertz R, Croop R, Liu J.   +9 more
europepmc   +1 more source

Efficacy and Safety of Rimegepant 75 Mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial [Corrigendum]

Journal of Pain Research
Lipton RB, Thiry A, Morris BA, Croop R. J Pain Res. 2024 Jul 22:17:2431–2441. The authors have advised that Figure 2 on page 2437 is incorrect. The text “150/241 (27.7%)” in the Placebo n/N (Risk) column for the row Freedom from MBS ...
Lipton RB, Thiry A, Morris BA, Croop R
doaj  

Gepants for headache prevention in children and adolescents: A multicenter chart review study. [PDF]

Headache
Shin L, Mentz O, Gelfand AA, de Prado BM, Shapiro H, Oh A, Onifade OO, Saunders J, Raj N, Szperka CL.   +9 more
europepmc   +1 more source